Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
america   source : Ir.vaccinex.com    save search
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
Published: 2022-03-09 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $5.005 0.84% -2.76% 3.3K twitter stocktwits trandingview |
Health Technology
 | | O: 1.83% H: 18.92% C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer vaccine phase 2b
Gainers vs Losers
61% 39%

Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M twitter stocktwits trandingview |
Consumer Services
BOF | $2.08 77.78% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.54 12.27% 40.62% 3.7M twitter stocktwits trandingview |

LICN | $0.999 78.39% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.4 70.0% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.458 14.5% 30.92% 91K twitter stocktwits trandingview |
Health Services
WHLM | $6.25 35.87% 28.46% 700K twitter stocktwits trandingview |
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M twitter stocktwits trandingview |
Information
Your saved searches
Save your searches and get alerts when important news are released.